These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31449666)

  • 1. A Minimal Physiologically-Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug-Disease Interactions With Antibody Therapy.
    Abdallah HM; Zhu AZX
    Clin Pharmacol Ther; 2020 Feb; 107(2):423-434. PubMed ID: 31449666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
    Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
    Yuan D; Rode F; Cao Y
    AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
    Fau JB; El-Cheikh R; Brillac C; Koiwai K; Mace N; Campana F; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):649-658. PubMed ID: 33021075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.
    Malik PRV; Hamadeh A; Edginton AN
    Pharm Res; 2022 Feb; 39(2):239-250. PubMed ID: 35118567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human FcRn Tissue Expression Profile and Half-Life in PBMCs.
    Fan YY; Farrokhi V; Caiazzo T; Wang M; O'Hara DM; Neubert H
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31443181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model.
    Roy S; Nanovskaya T; Patrikeeva S; Cochran E; Parge V; Guess J; Schaeck J; Choudhury A; Ahmed M; Ling LE
    Am J Obstet Gynecol; 2019 May; 220(5):498.e1-498.e9. PubMed ID: 30849355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
    Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
    Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance.
    Goulet DR; Watson MJ; Tam SH; Zwolak A; Chiu ML; Atkins WM; Nath A
    Drug Metab Dispos; 2018 Dec; 46(12):1900-1907. PubMed ID: 30232177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys.
    Li T; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):701-713. PubMed ID: 30423340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.